Chongqing Genrix Biopharmaceutical Co., Ltd. (SHA:688443)
China · Delayed Price · Currency is CNY 26.11
+1.02 (4.07%)
Mar 27, 2026, 4:00 PM EDT
SHA:688443 Revenue
In the year 2025, Chongqing Genrix Biopharmaceutical had annual revenue of 230.72M CNY with 666.65% growth. Chongqing Genrix Biopharmaceutical had revenue of 23.17M in the quarter ending December 31, 2025, with 31.58% growth.
Revenue
230.72M
Revenue Growth
+666.65%
P/S Ratio
41.50
Revenue / Employee
310.53K
Employees
793
Market Cap
9.57B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 230.72M | 200.63M | 666.65% |
| Dec 31, 2024 | 30.09M | 28.88M | 2,384.11% |
| Dec 31, 2023 | 1.21M | 736.26K | 154.92% |
| Dec 31, 2022 | 475.24K | -38.72M | -98.79% |
| Dec 31, 2021 | 39.19M | 38.10M | 3,502.99% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| China Resources Boya Bio-pharmaceutical Group Co.,Ltd | 2.06B |
| Jiangsu Sinopep-Allsino Biopharmaceutical | 1.94B |
| Aurisco Pharmaceutical | 1.62B |
| Liaoning Chengda Biotechnology | 1.39B |
| Jiangxi Fushine Pharmaceutical | 1.18B |
| Hualan Biological Vaccine | 976.44M |
| Bio-Thera Solutions | 933.69M |
| Daan Gene | 765.48M |